Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Campus Vienna Biocenter - Progress on Alzheimer’s Vaccine

16.09.2005


An innovative vaccination can significantly reduce deposits of the substances in the brain responsible for causing Alzheimer’s disease. This result was disclosed today by Affiris GmbH, a company located at the Campus Vienna Biocenter, Austria. The rapid progress during the pre-clinical development phase has already enabled the Vienna-based company, although having operated only since April 2004, to plan clinical trials for 2006, and thus proves the international competitiveness of the Campus Vienna Biocenter.



Beta-amyloids are pathological fragments of a normal brain protein. They are responsible for the development of Alzheimer’s disease, as they cause the death of brain cells. Amyloid fragments are found in large amounts in the cerebral fluid of Alzheimer patients. Deposits are formed in the brain over the years, thus creating the plaque structures typical of Alzheimer’s disease. It has not yet been completely clarified whether plaque formation or the soluble beta-amyloids are the causative agents for Alzheimer’s disease.

Tailor-made Vaccine


The Vienna-based company Affiris is now reporting that it has succeeded in significantly reducing Alzheimer plaques by at least two-thirds in pre-clinical models by means of an innovative vaccine. CEO Dr. Walter Schmidt explains the important feature of the vaccination strategy: "Alzheimer’s is caused by a fragment of one of the ubiquitous proteins of cerebral cells. If one wants to combat Alzheimer immunologically it is essential to generate antibodies which are targeted against the beta-amyloids, but which leave the normal constituent of the cerebral cells unharmed, since the latter would induce an autoimmune disease. In keeping with this, Affiris´ vaccine approach has been shown to be highly specific for beta amyloids and not to react with the normal constituent of cerebral cells."

Thus, the Affiris approach not only avoids an autoimmune disease, but also offers the advantage of targeting simultaneously both the plaques and the soluble beta-amyloid fraction. Therefore, whether the soluble or plaque forms - or both - are responsible for causing the disease is not ultimately crucial for the vaccine’s success. The additional proof that the vaccine induces antibodies, which are active against plaques in human tissue samples, and the first data collected on the toxicology profile have further contributed to built a secure basis for Affiris to schedule the first trials on patients for 2006.

Biotech with Economics

Beside its scientific success Affiris also boasts important economic advantages: low costs and short manufacturing times for its vaccine. In the words of Dr. Schmidt: "Our substances are produced at low costs and a building-block system is used to form the vaccine. The effective component is synthetically manufactured and combined with a carrier substance isolated from natural resources. Both together form the actual vaccine and a standard adjuvant is added to strengthen the immune response."

The fact that the management has taken these important economic aspects into consideration from the very beginning is also due to the comprehensive biotech experiences at the Campus Vienna Biocenter. After all, numerous biotech companies and research institutes are situated at the Campus Vienna Biocenter, in addition to the FH Campus Wien (biotechnology), the Life Science Departments of the University of Vienna and the Medical University of Vienna, all sharing both resources and experiences and thus contributing to the international success of this location.

About AFFiRiS (September 2005):

AFFiRiS develops peptide-based vaccines for the treatment of Alzheimer’s disease and atherosclerosis. The company has established platform technologies and registered seven patents. 12 employees work in a 6,500 sqf rented laboratory facility on the Campus Vienna Biocenter.

About the Campus Vienna Biocenter (September 2005):

The Campus Vienna Biocenter is one of the largest R&D clusters in Austria with approx. 1,000 scientists from 40 nations at 16 organisations. Academic departments (University of Vienna, Medical University of Vienna, subsumed in the Max F. Perutz Laboratories), private research institutes (IMP - Institute of Molecular Pathology) and institutes of the Austrian Academy of Sciences (IMBA - Institute of Molecular Biotechnology, GMI - Gregor Mendel Institute) are also located here along with commercial R&D companies, service companies and training course centres.

Till C. Jelitto | alfa
Further information:
http://www.prd.at
http://www.affiris.com
http://www.viennabiocenter.com

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nonstop Tranport of Cargo in Nanomachines

Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.

Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

When AI and optoelectronics meet: Researchers take control of light properties

20.11.2018 | Physics and Astronomy

Researchers use MRI to predict Alzheimer's disease

20.11.2018 | Medical Engineering

How to melt gold at room temperature

20.11.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>